Clinical Scorecard: Lysophosphatidylcholine and lysophosphatidic acid: pivotal signaling molecules in atherosclerosis and their potential for therapeutic application

At a Glance

Key Highlights

• LPC and LPA are central to the lipid-inflammation pathogenic cycle in atherosclerosis.
• Hyperlipidemia leads to the production of LPC and LPA, driving inflammatory signaling.
• Spatial metabolomics identifies LPC and LPA enrichment in macrophage-rich regions of plaques.
• Current therapies targeting Lp-PLA2 and autotaxin have shown limited clinical success.
• Emerging strategies include multi-node combination therapy targeting lipid metabolism and inflammation.

Guideline-Based Recommendations

Diagnosis

• Assess lipid profiles and inflammatory markers in patients with atherosclerosis.

Management

• Consider therapies targeting LPC and LPA signaling pathways.

Monitoring & Follow-up

• Monitor plasma levels of LPC and LPA as potential biomarkers for cardiovascular risk.

Risks

• Patients with atherosclerosis remain at risk for cardiovascular events despite lipid-lowering therapies.

Patient & Prescribing Data

Individuals with atherosclerosis and high residual cardiovascular risk.

Current therapies may need to be complemented with strategies targeting LPL signaling.

Clinical Best Practices

• Integrate lipid and inflammatory assessments in managing atherosclerosis.
• Utilize spatial metabolomics for understanding plaque composition and risk.
• Explore combination therapies that address multiple pathways in atherosclerosis.

Related Resources & Content

• Global Burden of Disease Study
• Clinical Trials of Lp-PLA2 and Autotaxin Inhibitors